• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Defining the 90-day cost structure of lower extremity revascularization for alternative payment model assessment.定义下肢血运重建的 90 天成本结构,以评估替代支付模式。
J Vasc Surg. 2021 Feb;73(2):662-673.e3. doi: 10.1016/j.jvs.2020.06.050. Epub 2020 Jul 8.
2
The Society for Vascular Surgery Alternative Payment Model Task Force report on opportunities for value-based reimbursement in care for patients with peripheral artery disease.血管外科学会替代支付模式工作组关于在外周动脉疾病患者护理中基于价值的报销机会的报告。
J Vasc Surg. 2021 Apr;73(4):1404-1413.e2. doi: 10.1016/j.jvs.2020.08.131. Epub 2020 Sep 12.
3
Medicare reimbursement of lower extremity bypass does not cover cost of care for most patients with critical limb ischemia.医疗保险对下肢旁路手术的报销并不涵盖大多数有严重肢体缺血的患者的治疗费用。
J Vasc Surg. 2020 Sep;72(3):1068-1074. doi: 10.1016/j.jvs.2020.01.062.
4
Factors associated with 90-day reintervention following lower extremity revascularization.与下肢血运重建后 90 天再干预相关的因素。
J Vasc Surg. 2024 Jul;80(1):213-222.e1. doi: 10.1016/j.jvs.2024.03.009. Epub 2024 Mar 8.
5
A real world analysis of payment per unit time in a Maryland Vascular Practice.马里兰州血管病诊治实践中按单位时间付费的真实世界分析。
J Vasc Surg. 2010 Oct;52(4):1094-8; discussion 1098-9. doi: 10.1016/j.jvs.2010.04.072.
6
Refining risk adjustment for bundled payment models in cervical fusions-an analysis of Medicare beneficiaries.对颈椎融合术捆绑支付模型进行风险调整的精细化研究——以 Medicare 受益人为例。
Spine J. 2019 Oct;19(10):1706-1713. doi: 10.1016/j.spinee.2019.06.009. Epub 2019 Jun 18.
7
The disproportionate growth of office-based atherectomy.基于办公室的斑块旋切术的不成比例增长。
J Vasc Surg. 2017 Feb;65(2):495-500. doi: 10.1016/j.jvs.2016.08.112. Epub 2016 Dec 13.
8
Are we ready for bundled payments for major bowel surgery?我们是否已经准备好为主要肠道手术进行捆绑式支付?
Surg Endosc. 2020 Nov;34(11):4950-4956. doi: 10.1007/s00464-019-07287-8. Epub 2019 Dec 10.
9
2018 John Charnley Award: Analysis of US Hip Replacement Bundled Payments: Physician-initiated Episodes Outperform Hospital-initiated Episodes.2018 年约翰·查恩利奖:美国髋关节置换捆绑支付分析:医生发起的病例优于医院发起的病例。
Clin Orthop Relat Res. 2019 Feb;477(2):271-280. doi: 10.1097/CORR.0000000000000532.
10
Drivers of Variation in 90-Day Episode Payments After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后 90 天内的支付变化的驱动因素。
Circ Cardiovasc Interv. 2019 Jan;12(1):e006928. doi: 10.1161/CIRCINTERVENTIONS.118.006928.

引用本文的文献

1
Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value.基于聚合物的药物洗脱支架治疗可延长有症状股腘动脉疾病患者的再次介入治疗时间:临床证据和潜在经济价值。
J Comp Eff Res. 2024 Jun;13(6):e240025. doi: 10.57264/cer-2024-0025. Epub 2024 Apr 12.

本文引用的文献

1
Characteristics of high-cost inpatients with peripheral artery disease.外周动脉疾病高费用住院患者的特征。
J Vasc Surg. 2020 Jul;72(1):250-258.e8. doi: 10.1016/j.jvs.2019.09.054. Epub 2020 Jan 21.
2
A systematic review and meta-analysis of risk factors for and incidence of 30-day readmission after revascularization for peripheral artery disease.外周动脉疾病血运重建术后 30 天再入院风险因素及发生率的系统评价和荟萃分析。
J Vasc Surg. 2019 Sep;70(3):996-1006.e7. doi: 10.1016/j.jvs.2019.01.079.
3
Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Competitive Bidding Program (CBP) and Fee Schedule Amounts, and Technical Amendments To Correct Existing Regulations Related to the CBP for Certain DMEPOS. Final rule.医疗保险计划;终末期肾病前瞻性支付系统、向急性肾损伤患者提供的肾透析服务支付、终末期肾病质量激励计划、耐用医疗设备、假肢、矫形器及用品(DMEPOS)竞争性投标计划(CBP)和费用表金额,以及纠正与某些DMEPOS的CBP相关现行法规的技术修订。最终规则。
Fed Regist. 2018 Nov 14;83(220):56922-7073.
4
Medicare risk-adjusted outcomes in elective major vascular surgery.医疗保险调整后择期大血管手术的结果。
Surgery. 2018 Oct;164(4):831-838. doi: 10.1016/j.surg.2018.03.025. Epub 2018 Jun 22.
5
Field testing for the critical limb ischemia cost measure.严重肢体缺血成本测量的现场测试。
J Vasc Surg. 2018 Jun;67(6):1933. doi: 10.1016/j.jvs.2018.04.013.
6
Evaluating Quality Metrics and Cost After Discharge: A Population-based Cohort Study of Value in Health Care Following Elective Major Vascular Surgery.评估出院后的质量指标和成本:一项基于人群的在择期大血管手术后医疗保健价值的队列研究。
Ann Surg. 2019 Aug;270(2):378-383. doi: 10.1097/SLA.0000000000002767.
7
Regional variation in the cost of infrainguinal lower extremity bypass surgery in the United States.美国下肢动静脉旁路手术的成本在地区间存在差异。
J Vasc Surg. 2018 Apr;67(4):1170-1180.e4. doi: 10.1016/j.jvs.2017.08.055. Epub 2017 Oct 23.
8
Short- and long-term readmission rates after infrainguinal bypass in a safety net hospital are higher than expected.在一家安全网医院中,腹股沟下旁路手术后的短期和长期再入院率高于预期。
J Vasc Surg. 2017 Dec;66(6):1786-1791. doi: 10.1016/j.jvs.2017.07.120. Epub 2017 Sep 29.
9
Hospital readmissions after elective lower extremity vascular procedures.择期下肢血管手术后的医院再入院情况。
Vascular. 2018 Jun;26(3):250-261. doi: 10.1177/1708538117728637. Epub 2017 Sep 20.
10
Estimated annual health care expenditures in individuals with peripheral arterial disease.外周动脉疾病患者的年估计医疗保健支出。
J Vasc Surg. 2018 Feb;67(2):558-567. doi: 10.1016/j.jvs.2017.06.102. Epub 2017 Aug 25.

定义下肢血运重建的 90 天成本结构,以评估替代支付模式。

Defining the 90-day cost structure of lower extremity revascularization for alternative payment model assessment.

机构信息

Division of Vascular Surgery and Endovascular Therapy, Emory University, Atlanta, Ga.

University of Massachusetts Medical School, Worcester, Mass.

出版信息

J Vasc Surg. 2021 Feb;73(2):662-673.e3. doi: 10.1016/j.jvs.2020.06.050. Epub 2020 Jul 8.

DOI:10.1016/j.jvs.2020.06.050
PMID:32652115
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8189630/
Abstract

BACKGROUND

The U.S. healthcare system is undergoing a broad transformation from the traditional fee-for-service model to value-based payments. The changes introduced by the Medicare Quality Payment Program, including the establishment of Alternative Payment Models, ensure that the practice of vascular surgery is likely to face significant reimbursement changes as payments transition to favor these models. The Society for Vascular Surgery Alternative Payment Model taskforce was formed to explore the opportunities to develop a physician-focused payment model that will allow vascular surgeons to continue to deliver the complex care required for peripheral arterial disease (PAD).

METHODS

A financial analysis was performed based on Medicare beneficiaries who had undergone qualifying index procedures during fiscal year 2016 through the third quarter of 2017. Index procedures were defined using a list of Healthcare Common Procedural Coding (HCPC) procedure codes that represent open and endovascular PAD interventions. Inpatient procedures were mapped to three diagnosis-related group (DRG) families consistent with PAD conditions: other vascular procedures (codes, 252-254), aortic and heart assist procedures (codes, 268, 269), and other major vascular procedures (codes, 270-272). Patients undergoing outpatient or office-based procedures were included if the claims data were inclusive of the HCPC procedure codes. Emergent procedures, patients with end-stage renal disease, and patients undergoing interventions within the 30 days preceding the index procedure were excluded. The analysis included usage of postacute care services (PACS) and 90-day postdischarge events (PDEs). PACS are defined as rehabilitation, skilled nursing facility, and home health services. PDEs included emergency department visits, observation stays, inpatient readmissions, and reinterventions.

RESULTS

A total of 123,180 cases were included. Of these 123,180 cases, 82% had been performed in the outpatient setting. The Medicare expenditures for all periprocedural services provided at the index procedure (ie, professional, technical, and facility fees) were higher in the inpatient setting, with an average reimbursement per index case of $18,755, $34,600, and $25,245 for DRG codes 252 to 254, DRG codes 268 and 269, and DRG codes 270 to 272, respectively. Outpatient facility interventions had an average reimbursement of $11,458, and office-based index procedures had costs of $11,533. PACS were more commonly used after inpatient index procedures. In the inpatient setting, PACS usage and reimbursement were 58.6% ($5338), 57.2% ($4192), and 55.9% ($5275) for DRG codes 252 to 254, DRG codes 268 and 269, and DRG codes 270 to 272, respectively. Outpatient facility cases required PACS for 13.7% of cases (average cost, $1352), and office-based procedures required PACS in 15% of cases (average cost, $1467). The 90-day PDEs were frequent across all sites of service (range, 38.9%-50.2%) and carried significant costs. Readmission was associated with the highest average PDE expenditure (range, $13,950-$18.934). The average readmission Medicare reimbursement exceeded that of the index procedures performed in the outpatient setting.

CONCLUSIONS

The cost of PAD interventions extends beyond the index procedure and includes relevant spending during the long postoperative period. Despite the analysis challenges related to the breadth of vascular procedures and the site of service variability, the data identified potential cost-saving opportunities in the management of costly PDEs. Because of the vulnerability of the PAD patient population, alternative payment modeling using a bundled value-based approach will require reallocation of resources to provide longitudinal patient care extending beyond the initial intervention.

摘要

背景

美国医疗保健系统正在从传统的按服务收费模式向基于价值的支付模式进行广泛转型。医疗保险质量支付计划(Medicare Quality Payment Program)引入的变化,包括建立替代支付模式,确保血管外科学实践可能面临重大的报销变化,因为支付方式转向有利于这些模式。为了探索开发一种以医生为中心的支付模式的机会,使血管外科医生能够继续提供外周动脉疾病(PAD)所需的复杂护理,成立了血管外科学替代支付模式工作组。

方法

根据 2016 财年至 2017 年第三季度期间接受符合条件的索引程序的医疗保险受益人进行了财务分析。索引程序使用代表开放和血管内 PAD 干预的医疗保健通用程序编码(HCPC)程序代码列表进行定义。住院程序与符合 PAD 条件的三个诊断相关组(DRG)家族相关联:其他血管程序(代码 252-254)、主动脉和心脏辅助程序(代码 268、269)和其他主要血管程序(代码 270-272)。如果索赔数据包含 HCPC 程序代码,则包括门诊或办公室程序的患者。排除急诊程序、终末期肾病患者和索引程序前 30 天内进行干预的患者。分析包括使用急性后护理服务(PACS)和 90 天出院后事件(PDEs)。PACS 定义为康复、熟练护理机构和家庭保健服务。PDEs 包括急诊就诊、观察停留、住院再入院和再介入。

结果

共纳入 123180 例。在这些 123180 例中,82%在门诊环境中进行。索引程序(即专业、技术和设施费用)提供的所有围手术期服务的医疗保险支出在住院环境中更高,每个索引病例的平均报销额分别为 DRG 代码 252 至 254 为 18755 美元、DRG 代码 268 和 269 为 34600 美元、DRG 代码 270 至 272 为 25245 美元。门诊设施干预的平均报销额为 11458 美元,门诊索引程序的费用为 11533 美元。住院索引程序后更常使用 PACS。在住院环境中,PACS 使用和报销分别为 58.6%(5338 美元)、57.2%(4192 美元)和 55.9%(5275 美元),DRG 代码 252 至 254、DRG 代码 268 和 269、DRG 代码 270 至 272。门诊设施病例中有 13.7%(平均费用为 1352 美元)需要 PACS,而办公室程序中有 15%(平均费用为 1467 美元)需要 PACS。所有服务地点(范围 38.9%-50.2%)的 90 天 PDE 都很频繁,并且费用很高。再入院与最高平均 PDE 支出相关(范围 13950-18934 美元)。再入院的医疗保险报销额超过了门诊环境中进行的索引程序。

结论

PAD 干预的成本超出了索引程序的范围,包括术后长期相关的支出。尽管与血管手术的广泛范围和服务地点的可变性相关的分析挑战,但数据确定了在管理昂贵的 PDE 方面有潜在的节省成本的机会。由于 PAD 患者群体的脆弱性,使用捆绑基于价值的方法的替代支付模式将需要重新分配资源,为初始干预后延长的纵向患者护理提供支持。